Gallbladder carcinoma is the most common primary malignant tumor of the gallbladder, accounting for 2-3% of gastrointestinal cancers. Histologically, over 90% are adenocarcinomas. It is 2-3 times more common in women than men and is usually diagnosed between ages 60-70. Cholelithiasis is the most important risk factor (present in 70-90% of cases). Porcelain gallbladder, gallbladder polyps larger than 10 mm, and chronic inflammation are other risk factors. In early stages, it presents as focal or diffuse wall thickening; in advanced stages, it appears as a mass filling the gallbladder lumen or completely replacing the gallbladder with liver invasion. It is usually advanced at diagnosis because it does not produce early symptoms and mimics cholecystitis.
Age Range
50-85
Peak Age
70
Gender
Female predominant
Prevalence
Uncommon
The pathogenesis of gallbladder carcinoma is based on the chronic inflammation-dysplasia-carcinoma sequence. Chronic mucosal irritation and inflammation due to cholelithiasis predisposes to epithelial dysplasia development. Mechanical irritation by gallstones and chronic exposure to bile salts leads to DNA damage in mucosal cells and mutations in genes such as p53 and KRAS. The metaplasia-dysplasia-carcinoma in situ-invasive carcinoma sequence typically takes 5-15 years. In porcelain gallbladder, the calcified wall is a consequence of chronic inflammation with reported malignancy risk of 12-60%. The tumor spreads rapidly along the gallbladder wall because the serosal layer is thin and absent at the liver bed — this anatomical feature facilitates direct liver invasion. On imaging, early stage is reflected as irregular wall thickening and mucosal irregularity; advanced stage shows heterogeneously enhancing mass, liver invasion, and biliary obstruction.
In advanced stage, the gallbladder is no longer identifiable; instead, a heterogeneously enhancing mass filling the gallbladder fossa and invading liver segments IVb-V is seen. The most common presentation (40-60%).
Heterogeneously enhancing mass partially or completely filling/replacing the gallbladder in the gallbladder fossa on portal venous phase. In advanced stages, the gallbladder is no longer recognizable and is replaced by an irregularly marginated heterogeneous soft tissue mass. The mass shows moderate enhancement with non-enhancing necrotic areas. Direct invasion of liver segments IVb and V is common.
Report Sentence
A heterogeneously enhancing soft tissue mass replacing the gallbladder in the gallbladder fossa is identified, consistent with gallbladder carcinoma; invasion of liver segments IVb and V should be evaluated.
Irregular, asymmetric wall thickening with early mucosal enhancement in the arterial phase. Wall thickness is usually >10 mm and may be focal or diffuse. Mucosal surface irregularity, polypoid protrusion, or ulceration may be observed. Early arterial enhancement reflects tumor neovascularity. This pattern is particularly seen in early stage (T1-T2) gallbladder carcinoma.
Report Sentence
Irregular, asymmetric gallbladder wall thickening with early enhancement in the arterial phase is identified, suspicious for gallbladder carcinoma.
On US, gallbladder carcinoma appears in three patterns: (1) Heterogeneous echogenic mass filling lumen/extending from wall — most common (40-60%); (2) Focal or diffuse asymmetric wall thickening (>10 mm); (3) Mass replacing gallbladder — advanced stage. Vascularity on color Doppler favors malignancy. Accompanying gallstones (70-90%) and intrahepatic bile duct dilatation are common.
Report Sentence
A heterogeneous echogenic mass filling the gallbladder lumen with vascularity on Doppler examination is identified; gallbladder carcinoma should be primarily considered.
Gallbladder carcinoma shows marked diffusion restriction on DWI — high signal on high b-value and low signal on ADC map. ADC values are typically <1.2 x 10⁻³ mm²/s. Diffusion restriction reflects high cellularity and is the most valuable MRI finding for differentiating from benign wall thickening (adenomyomatosis, chronic cholecystitis).
Report Sentence
Marked diffusion restriction (low ADC) in the area of gallbladder wall thickening/mass is identified, consistent with malignant process; gallbladder carcinoma should be considered.
On T2-weighted MRI, gallbladder carcinoma shows intermediate-to-high heterogeneous signal intensity. The solid component shows intermediate T2 signal while necrotic and cystic areas show high T2 signal. The tumor is distinguished from bile-filled lumen as solid tissue. Peripheral edema at the liver invasion zone appears as high T2 signal.
Report Sentence
A soft tissue mass with heterogeneous signal on T2-weighted sequences is identified in the gallbladder fossa, consistent with gallbladder carcinoma.
Gallbladder carcinoma shows avid FDG uptake on PET-CT (SUVmax typically >5). Primary tumor metabolic activity, regional lymph node metastases, and distant metastases (liver, peritoneum, bone) can be simultaneously evaluated. PET-CT sensitivity is 85-95% and specificity 80-90%. Chronic cholecystitis and xanthogranulomatous cholecystitis can show low-moderate FDG uptake (SUVmax 2-4) — a source of false positives.
Report Sentence
Avid FDG uptake in the gallbladder fossa mass is identified, consistent with gallbladder carcinoma; regional and distant metastasis should be evaluated.
Criteria
Solid mass filling or replacing the gallbladder. Most common (40-60%). Direct liver invasion characteristic in advanced stages.
Distinct Features
Heterogeneous enhancement, central necrosis, irregular margins. Direct invasion facilitated by absent serosa at liver bed. Hepatoduodenal ligament LAP and peritoneal spread common.
Criteria
Focal or diffuse asymmetric wall thickening (>10 mm). 20-30% of cases. Early stage (T1-T2). Differential from chronic cholecystitis challenging.
Distinct Features
DWI diffusion restriction differentiates from benign thickening. Mucosal irregularity, early arterial enhancement, and asymmetry favor malignancy. Pericholecystic fat infiltration suggests advanced stage.
Criteria
Polypoid mass extending from wall into lumen (>10 mm). 15-25% of cases. Size (>10 mm), broad base, and vascularity important for differentiation from benign polyps.
Distinct Features
Broad-based, irregular surface, >10 mm polyp increases malignancy risk. Doppler hypervascularity and DWI diffusion restriction favor malignancy. Cholecystectomy for >10 mm or rapidly growing.
Distinguishing Feature
In adenomyomatosis, comet-tail artifacts and intramural cystic foci are diagnostic; regular mucosa, no diffusion restriction. In carcinoma, no comet-tail, irregular mucosa, marked diffusion restriction.
Distinguishing Feature
In xanthogranulomatous cholecystitis, intramural nodules and pericholecystic inflammation are prominent; no liver parenchymal invasion. In carcinoma, liver invasion, vascular ensheathment, and metastatic LAP differentiate.
Distinguishing Feature
In chronic cholecystitis, wall thickening is smooth and symmetric with no/minimal DWI restriction. In carcinoma, asymmetric, irregular thickening and marked diffusion restriction (low ADC).
Distinguishing Feature
In intrahepatic cholangiocarcinoma, mass is within liver, independent of gallbladder; shows delayed enhancement. In GB carcinoma, mass is centered on gallbladder fossa with continuity to gallbladder.
Urgency
urgentManagement
surgicalBiopsy
NeededFollow-up
specialist-referralPrognosis is stage-dependent. At T1a, simple cholecystectomy sufficient (5-year survival >85%). T1b+ requires radical cholecystectomy (segments IVb-V resection + LAP dissection). >50% advanced (T3-T4) at diagnosis. Chemotherapy (gemcitabine + cisplatin) palliative for inoperable cases. Biliary stenting for obstruction.
Gallbladder carcinoma is an aggressive tumor and may be difficult to diagnose early. It can be incidentally detected in cholecystectomy specimens. T1/T2 stages are treated with cholecystectomy, T3 and above require extended resection. Overall prognosis is poor (5-year survival <20%).